Evidence map›Paper›PMID 41488202›Full record

ReviewBiochemistry and biophysics reports2026

MicroRNA-181a in acute lymphoblastic leukemia: expression pattern, target genes and its potential as a biomarker.

Mohammad Jahanpanah, Abtin Ghasempour, Diana Mokhtari, Shirin Eshghi, Mahsa Mousakhan Bakhtiari, Mohammad Taha Salmanifard Ardestani, Leila Jafari, Maryam Behfar, Amir Ali Hamidieh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad JahanpanahPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abtin GhasempourPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Diana MokhtariPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Shirin EshghiPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mahsa Mousakhan BakhtiariPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Taha Salmanifard ArdestaniPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Leila JafariPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Maryam BehfarPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Amir Ali HamidiehPediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The exact etiology of Acute Lymphoblastic Leukemia (ALL) is not yet fully understood. Inherited genetic abnormalities and exposure to environmental risk factors are implicated in pathogenesis of ALL patients. Over the past two decades, epigenetic factors like microRNAs (miRs) have been in the spotlight and shown to have a pivotal role in the pathogenicity of ALL. MiRs are a group of small non-coding single-stranded RNAs (∼22 nucleotides) involved in post-transcriptional regulation of gene expression. MiR-181a has been shown to have a dual behavior in different types of cancers. This dual behavior of miR-181a shows that it should be investigated in a disease-specific manner. In this study, 24 studies were reviewed in different sections including the expression pattern of miR-181a, its target genes, and its potential as a biomarker in ALL from January 2000 to March 2025. Results of the reviewed studies conclusively indicate that miR-181a-5p is upregulated in pediatric ALL patients compared to normal control groups, and miR-181a-5p acts as an oncomir in pediatric ALL patients. Nevertheless, there are only a few studies in adults with inconclusive results. Furthermore, miR-181a-5p might be the upstream activator of the leukemic T-cell proliferation by having direct and indirect effects on several genes. Recent studies indicate that this miR can be implemented in diagnosing and classifying central nervous system (CNS) involvement in ALL patients, which is a devastating challenge in the field of hematology-oncology.

Indexed as

Acute lymphoblastic leukemiaMicroRNAsMiR-181aOncomirPediatric ALL

Identifiers

PMID41488202
PMCPMC12757578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.